{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:28:18Z","timestamp":1761870498016,"version":"build-2065373602"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.clml.2012.11.003","type":"journal-article","created":{"date-parts":[[2012,12,20]],"date-time":"2012-12-20T19:12:04Z","timestamp":1356030724000},"page":"112-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Phase I Clinical Trial of Valacyclovir and Standard of Care Cyclophosphamide in Children With Endemic Burkitt Lymphoma in Malawi"],"prefix":"10.1016","volume":"13","author":[{"given":"Daniel","family":"Olson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret L.","family":"Gulley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihua","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clifford","family":"Wokocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oren","family":"Mechanic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Hosseinipour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart H.","family":"Gold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelson","family":"Nguluwe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Mwansambo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Shores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2012.11.003_bib1","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMra032015","article-title":"Persistence of the Epstein-Barr virus and the origins of associated lymphomas","volume":"350","author":"Thorley-Lawson","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2012.11.003_bib2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2353\/jmoldx.2008.080023","article-title":"Laboratory assays for Epstein-Barr virus-related disease","volume":"10","author":"Gulley","year":"2008","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.clml.2012.11.003_bib3","first-page":"165","article-title":"Epstein-Barr virus and Burkitt's lymphoma worldwide: the causal relationship revisited","volume":"60","author":"de-Th\u00e9","year":"1985","journal-title":"IARC Sci Publ"},{"key":"10.1016\/j.clml.2012.11.003_bib4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/mpo.10190","article-title":"Long term survival of children with Burkitt lymphoma in Malawi after cyclophosphamide monotherapy","volume":"40","author":"Kazembe","year":"2003","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.clml.2012.11.003_bib5","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/intimm\/dxh099","article-title":"Determining virological, serological and immunological parameters of EBV infection in the development of PTLD","volume":"16","author":"Davis","year":"2004","journal-title":"Int Immunol"},{"key":"10.1016\/j.clml.2012.11.003_bib6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1034\/j.1600-6143.2001.10202.x","article-title":"Management of Epstein-Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation","volume":"1","author":"Green","year":"2001","journal-title":"Am J Transplant"},{"key":"10.1016\/j.clml.2012.11.003_bib7","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1046\/j.1600-6143.2003.00325.x","article-title":"Lymphomas after solid organ transplantation: a collaborative transplant study report","volume":"4","author":"Opelz","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.clml.2012.11.003_bib8","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1172\/JCI119315","article-title":"Epstein-Barr virus-specific cytotoxic T cell responses in HIV-1 infection: different kinetics in patients progressing to opportunistic infection or non-Hodgkin's lymphoma","volume":"99","author":"Kersten","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clml.2012.11.003_bib9","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1086\/652283","article-title":"Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies","volume":"50","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clml.2012.11.003_bib10","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/QAD.0b013e3283437f77","article-title":"Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy","volume":"25","author":"Achenbach","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.clml.2012.11.003_bib11","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1086\/656416","article-title":"Cancer as a cause of death among people with AIDS in the United States","volume":"51","author":"Simard","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clml.2012.11.003_bib12","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1365-2141.2005.05613.x","article-title":"AIDS-related lymphomas: from pathogenesis to pathology","volume":"130","author":"Carbone","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2012.11.003_bib13","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/ajh.21250","article-title":"HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases","volume":"83","author":"Castillo","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2012.11.003_bib14","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/0140-6736(91)91837-K","article-title":"Epstein-Barr virus in AIDS-related primary central nervous system lymphoma","volume":"338","author":"MacMahon","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2012.11.003_bib15","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1038\/sj.onc.1206548","article-title":"Virally targeted therapies for EBV-associated malignancies","volume":"22","author":"Israel","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2012.11.003_bib16","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1128\/JVI.78.4.1893-1902.2004","article-title":"Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas","volume":"78","author":"Feng","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.clml.2012.11.003_bib17","first-page":"5781","article-title":"Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies","volume":"60","author":"Westphal","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2012.11.003_bib18","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1182\/blood-2011-06-362434","article-title":"Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents","volume":"119","author":"Ghosh","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.11.003_bib19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0065-230X(06)97004-3","article-title":"Lytic cycle switches of oncogenic human gammaherpesviruses","volume":"97","author":"Miller","year":"2007","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.clml.2012.11.003_bib20","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1128\/JVI.01416-06","article-title":"Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes","volume":"81","author":"Wen","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.clml.2012.11.003_bib21","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1158\/1078-0432.CCR-09-2424","article-title":"Viral response to chemotherapy in endemic burkitt lymphoma","volume":"16","author":"Tang","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2012.11.003_bib22","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.1073\/pnas.77.9.5163","article-title":"Acyclovir inhibition of Epstein-Barr virus replication","volume":"77","author":"Datta","year":"1980","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2012.11.003_bib23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jcv.2007.02.002","article-title":"A virologic pilot study of valacyclovir in infectious mononucleosis","volume":"39","author":"Balfour","year":"2007","journal-title":"J Clin Virol"},{"key":"10.1016\/j.clml.2012.11.003_bib24","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/MOH.0b013e328339018c","article-title":"Treatment advances in posttransplant lymphoproliferative disease","volume":"17","author":"DiNardo","year":"2010","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.clml.2012.11.003_bib25","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/blood-2006-01-024703","article-title":"A phase 1\/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies","volume":"109","author":"Perrine","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.11.003_bib26","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00043426-199122000-00019","article-title":"African Burkitt's lymphoma","volume":"13","author":"Magrath","year":"1991","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"10.1016\/j.clml.2012.11.003_bib27","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V97.11.3370","article-title":"The Societe Francaise d'Oncologie P\u00e9diatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia","volume":"97","author":"patte","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.11.003_bib28","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/pbc.20254","article-title":"The 2000 Burkitt lymphoma trial in Malawi","volume":"44","author":"Hesseling","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2012.11.003_bib29","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1111\/j.1600-6143.2005.01115.x","article-title":"Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients","volume":"5","author":"Funch","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.clml.2012.11.003_bib30","unstructured":"American Society of Hospital Pharmacists. AHFS Drug Information, 1989. Published by authority of the Board of Directors of the American Society of Hospital Pharmacists, Bethesda, MD: 1989:v"},{"key":"10.1016\/j.clml.2012.11.003_bib31","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2165\/11316080-000000000-00000","article-title":"Antivirals for cytomegalovirus infection in neonates and infants: focus on pharmacokinetics, formulations, dosing, and adverse events","volume":"11","author":"Marshall","year":"2009","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.clml.2012.11.003_bib32","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/sj.bmt.1703770","article-title":"Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation","volume":"30","author":"Burns","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2012.11.003_bib33","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/00126839-200203060-00001","article-title":"Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness","volume":"3","author":"Simon","year":"2002","journal-title":"Drugs R D"},{"issue":"suppl 1","key":"10.1016\/j.clml.2012.11.003_bib34","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1086\/342968","article-title":"An investigation of the steady-state pharmacokinetics of oral valacyclovir in immunocompromised children","volume":"186","author":"Nadal","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clml.2012.11.003_bib35","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/1097-0142(19871001)60:7<1651::AID-CNCR2820600738>3.0.CO;2-J","article-title":"The measurement of performance in childhood cancer patients","volume":"60","author":"Lansky","year":"1987","journal-title":"Cancer"},{"year":"2009","series-title":"Common Terminology Criteria For Adverse Events (CTCAE)","key":"10.1016\/j.clml.2012.11.003_bib36"},{"key":"10.1016\/j.clml.2012.11.003_bib37","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1525-1578(10)60535-1","article-title":"Epstein-Barr virus quantitation by real-time PCR targeting multiple gene segments: a novel approach to screen for the virus in paraffin-embedded tissue and plasma","volume":"6","author":"Ryan","year":"2004","journal-title":"J Mol Diagn"},{"year":"1979","series-title":"The United States pharmacopeia","key":"10.1016\/j.clml.2012.11.003_bib38"},{"key":"10.1016\/j.clml.2012.11.003_bib39","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1056\/NEJMoa072727","article-title":"Severe anemia in Malawian children","volume":"358","author":"Calis","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2012.11.003_bib40","first-page":"3254","article-title":"Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma","volume":"9","author":"To","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2012.11.003_bib41","first-page":"2351","article-title":"Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma","volume":"60","author":"Lo","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2012.11.003_bib42","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1002\/ijc.24223","article-title":"Epstein-Barr virus and the pathogenesis of Burkitt's lymphoma: more questions than answers","volume":"124","author":"Bornkamm","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2012.11.003_bib43","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1023\/A:1008363805242","article-title":"Discrepancies in Epstein-Barr virus association at presentation and relapse of classical Hodgkin's disease: impact on pathogenesis","volume":"11","author":"Nerurkar","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2012.11.003_bib44","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1200\/JCO.2004.05.178","article-title":"Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA","volume":"22","author":"Chan","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.11.003_bib45","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1056\/NEJMoa032260","article-title":"Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma","volume":"350","author":"Lin","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2012.11.003_bib46","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/ijc.20520","article-title":"Laboratory markers of tumor burden in nasopharyngeal carcinoma: a comparison of viral load and serologic tests for Epstein-Barr virus","volume":"112","author":"Fan","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2012.11.003_bib47","first-page":"5452","article-title":"Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma","volume":"59","author":"Lo","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2012.11.003_bib48","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/cncr.11833","article-title":"Children, cancer, and nutrition\u2014a dynamic triangle in review","volume":"100","author":"Sala","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2012.11.003_bib49","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/pbc.21697","article-title":"Nutritional status at admission of children with cancer in Malawi","volume":"51","author":"Isra\u00ebls","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.clml.2012.11.003_bib50","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3945\/an.110.000141","article-title":"Important aspects of nutrition in children with cancer","volume":"2","author":"Bauer","year":"2011","journal-title":"Adv Nutr"},{"key":"10.1016\/j.clml.2012.11.003_bib51","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/pbc.22032","article-title":"Malnutrition and neutropenia in children treated for Burkitt lymphoma in Malawi","volume":"53","author":"Isra\u00ebls","year":"2009","journal-title":"Pediatr Blood Cancer"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012002467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012002467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:23:20Z","timestamp":1761870200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265012002467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S2152265012002467"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2012.11.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I Clinical Trial of Valacyclovir and Standard of Care Cyclophosphamide in Children With Endemic Burkitt Lymphoma in Malawi","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2012.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}